Compare GBLI & CTKB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GBLI | CTKB |
|---|---|---|
| Founded | 2016 | 1990 |
| Country | United States | United States |
| Employees | 266 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 401.1M | 433.8M |
| IPO Year | 2003 | 2021 |
| Metric | GBLI | CTKB |
|---|---|---|
| Price | $28.00 | $4.99 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.88 |
| AVG Volume (30 Days) | 9.7K | ★ 1.8M |
| Earning Date | 10-30-2025 | 11-05-2025 |
| Dividend Yield | ★ 5.00% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.94 | N/A |
| Revenue | ★ $441,717,000.00 | $196,828,000.00 |
| Revenue This Year | $4.18 | N/A |
| Revenue Next Year | $8.77 | $5.62 |
| P/E Ratio | $14.46 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $25.88 | $2.37 |
| 52 Week High | $37.00 | $7.30 |
| Indicator | GBLI | CTKB |
|---|---|---|
| Relative Strength Index (RSI) | 46.13 | 49.02 |
| Support Level | $28.49 | $5.15 |
| Resistance Level | $29.48 | $5.50 |
| Average True Range (ATR) | 0.50 | 0.37 |
| MACD | 0.12 | -0.09 |
| Stochastic Oscillator | 58.89 | 5.95 |
Global Indemnity Group LLC provides both admitted and non-admitted specialty property and casualty insurance coverages and individual policyholder coverages in the United States, as well as reinsurance world-wide. The company's two segments are: Penn-America and Non-Core Operations. The Penn-America segment offers specialty property and casualty products designed for its Wholesale Commercial, Specialty Products, InsurTech, and Assumed Reinsurance product offerings. These product lines are offered in the excess and surplus lines marketplace; and Non-Core Operations segment contains lines of business that have been de-emphasized or are no longer being written. The majority of its revenue is from the the Penn-America segment . Geographically, the majority is from California.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.